

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2019 (15.08.2019)



(10) International Publication Number
WO 2019/157509 A1

(51) International Patent Classification:

A61K 39/02 (2006.01) *A61P 31/04* (2006.01)
A61K 39/39 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2019/017669

(22) International Filing Date:

12 February 2019 (12.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/629,513 12 February 2018 (12.02.2018) US

(71) Applicant: **INIMMUNE CORPORATION** [US/US];
1121 East Broadway, Suite 121, Missoula, Montana 59802
(US).

(72) Inventors: **BAZIN-LEE, Helene**; 4050 Wakantanka Way,
Stevensville, Montana 59870 (US). **ETTENDER, George**;
631 Pattee Creek Dr., Missoula, Montana 59801 (US).
KHALAF, Juhienah; 501 South 4th Street, Hamilton,
Montana 59840 (US). **RYTER, Kendal T.**; 263 Cartwright
Way, Hamilton, Montana 59840 (US).

(74) Agent: **CARROLL, William A.** et al.; 444 W. Lake Street,
Suite 3200, Chicago, Illinois 60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: TOLL-LIKE RECEPTOR LIGANDS

(57) Abstract: Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.

WO 2019/157509 A1